New hope for tough leukemia: experimental drug combo aims for remission
Disease control
Recruiting now
This study tests a new drug, L-Annamycin, combined with standard chemotherapy (cytarabine) in adults whose acute myeloid leukemia (AML) has returned or not responded to one prior treatment. The goal is to see if the combination can achieve complete remission (no signs of cancer) …
Phase: PHASE2, PHASE3 • Sponsor: Moleculin Biotech, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC